You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康恩貝(600572.SH)一季度淨利預增0%-10%
格隆匯 04-07 18:04

格隆匯4月7日丨康恩貝(600572.SH)發佈2020年第一季度業績預告,預計實現歸屬於上市公司股東的淨利潤與上年同期(法定披露數據)相比,將增加0萬元到1760萬元,同比增長0%-10%。扣除非經常性損益的淨利潤與上年同期(法定披露數據)相比,將減少3500萬元到4500萬元,同比下降約23%到30%。

公司2020年第一季度預計非經常性損益金額為6,700萬元到7700萬元,主要為公司子公司轉讓所持有的嘉和生物藥業有限公司境外上市主體JHBP (CY) Holdings Limited(以下簡稱“JHBP (CY)”)部分股權產生投資收益約5800萬元(税前,未經審計)。

公司全資子公司貴州拜特製藥有限公司(以下簡稱“貴州拜特公司”)核心產品丹蔘川芎嗪注射液受國家合理用藥重點監控目錄及醫保目錄調整等政策持續深化影響以及市場環境影響,2020年第一季度銷售收入同比減少約3.55億元,導致貴州拜特公司2020年第一季度淨利潤較上年同期同比減少約9200萬元。扣除貴州拜特公司核心產品丹蔘川芎嗪注射液銷售收入後,公司預計2020年第一季度營業收入約15.97億元,較2019年第一季度同口徑增長約22%。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account